The abstract is read at the publisher; the summary is JClub's.
Multimodal composite scoring detected ctDNA in 70% of CSF versus 17% of plasma samples from 28 pediatric CNS tumor patients, outperforming any single modality alone.
- Why it matters: Pediatric CNS ctDNA testing is limited by sensitivity and lacks universally accepted detection criteria, hindering reliable longitudinal disease monitoring.
- What they did: The study used longitudinal plasma and CSF from children with CNS tumors, applying targeted and whole genome sequencing with a tri-modal composite score (≥2) integrating mutation, copy number, and fragmentomic features.
- The result: Post-diagnosis plasma ctDNA positivity was linked to worse progression-free and overall survival, and CSF showed higher ctDNA signal intensity than plasma across assay modalities.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.